Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Syros Pharmaceuticals Inc SYRS

Healthcare Biotechnology
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARa), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in... see more

Recent & Breaking News (NDAQ:SYRS)

Syros Announces Strategic Priorities and Expected Milestones

Business Wire January 11, 2021

CORRECTING and REPLACING Syros to Present at 39th Annual J.P. Morgan Healthcare Conference

Business Wire January 7, 2021

Syros to Present at 39th Annual J.P. Morgan Healthcare Conference

Business Wire January 7, 2021

Syros Closes $90.5 Million Strategic Financing

Business Wire December 8, 2020

Syros Presents New Data From Phase 2 Clinical Trial of SY-1425 and Announces Plans to Initiate Registration-Enabling Trial in MDS and Randomized Phase 2 Trial in AML

Business Wire December 5, 2020

Syros Acquires Clinical-Stage Drug Candidate for Acute Promyelocytic Leukemia, Expanding Its Pipeline of Targeted Therapies for Hematologic Malignancies

Business Wire December 5, 2020

Syros Pharmaceuticals to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

Business Wire November 16, 2020

Syros Pharmaceuticals Reports Third Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Business Wire November 5, 2020

Syros to Present New Data from Phase 2 Clinical Trial of SY-1425 in Oral Presentations at 62nd ASH Annual Meeting

Business Wire November 4, 2020

Syros to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020

Business Wire October 29, 2020

Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral CDK7 Inhibitor, at EORTC-NCI-AACR Meeting

Business Wire October 24, 2020

Syros to Present Initial Data from Phase 1 Clinical Trial of SY-5609 at EORTC-NCI-AACR Meeting

Business Wire October 9, 2020

Syros Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference

Business Wire September 10, 2020

Syros Announces Appointment of S. Gail Eckhardt, M.D., to its Board of Directors

Business Wire September 9, 2020

Syros Reports Second Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Business Wire August 6, 2020

Syros Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

Business Wire August 5, 2020

Syros to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020

Business Wire July 30, 2020

Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing

PR Newswire July 7, 2020

Syros Announces Change to Presentation Time at JMP Securities Hematology and Oncology Forum

Business Wire June 17, 2020

Syros to Present Virtually at JMP Securities Hematology and Oncology Forum

Business Wire June 11, 2020